Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.ACST · Entity 7266 | CHIEF COMMERCIAL OFFICER | April 01, 2020 | April 01, 2020 |
| VERU INC.VERU · Entity 7234 | Chief Commercial Officer | December 14, 2017 | December 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date April 01, 2020 · Filed April 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2028-07-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-04-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F5: Canadian dollars. F1: Represents 300,000 common shares underlying 300,000 share options granted on July 2, 2018. These share options vest in 12 equal installments on a quarterly basis starting from July 2, 2018 until July 2, 2021. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2029-04-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-04-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F5: Canadian dollars. F2: Represents 34,000 common shares underlying 34,000 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2029-04-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-04-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F5: Canadian dollars. F3: Represents 116,000 common shares underlying 116,000 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2030-03-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-04-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F5: Canadian dollars. F4: Represents 587,000 common shares underlying 587,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a quarterly basis starting from March 31, 2020 until March 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 300,000 common shares underlying 300,000 share options granted on July 2, 2018. These share options vest in 12 equal installments on a quarterly basis starting from July 2, 2018 until July 2, 2021.
F2: Represents 34,000 common shares underlying 34,000 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
F3: Represents 116,000 common shares underlying 116,000 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
F4: Represents 587,000 common shares underlying 587,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a quarterly basis starting from March 31, 2020 until March 31, 2023.
F5: Canadian dollars.
VERU INC.
Report date December 14, 2017 · Filed December 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2027-12-14 | Direct | 97,335 |
Reported balance
After 2017-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-14 · Grant · Acquired 97,335 · Balance 97,335 F1: Options for all of the shares vest on December 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Options for all of the shares vest on December 14, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2017 Filed Dec 18, 2017 17:23 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 97,335 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001042167-17-000128 · primary_doc.xml · derivative · entry 1 Groch Brian J. · CIK 0001694429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,335 Underlying: Common Stock · 97.335 shares Expires 2027-12-14 F1 · derivative.exercise_date: Options for all of the shares vest on December 14, 2018. Read SEC document |
| December 04, 2017 Filed Dec 8, 2017 15:02 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 50,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001042167-17-000122 · primary_doc.xml · derivative · entry 1 Groch Brian J. · CIK 0001694429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-04 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of December 4, 2018, December 4, 2019 and December 4, 2020. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 16:37 UTC | VERU INC. FHCO · Entity 7234 | GrantCommon Stock Option · Derivative | 300,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001042167-17-000082 · primary_doc.xml · derivative · entry 1 Groch Brian J. · CIK 0001694429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-08-02 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of August 2, 2018, August 2, 2019 and August 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.